As raltitrexed and oxaliplatin (L-OHP) are both effective in the treatment of colorectal cancer but have different mechanisms of action, we studied the antitumoral activity and safety of their combined use in patients with advanced colorectal cancer.
Methods
A 15-min intravenous infusion of raltitrexed (2.5 mg/m2) and a 180-min infusion of oxaliplatin (100 mg/m2) were administered on day 1 every three weeks for a maximum of six cycles.
Results
The study involved 51 patients (27 males and 24 females) with a median age of 65 years (range, 43-78); 28 were aged ≥65 years. The primary tumor site was the colon in 35 patients and the rectum in 16. Thirty-four patients had received prior chemotherapy: 20 as adjuvant treatment and 14 as pretreatment. The most frequent metastatic sites were liver (18 cases), lung (10 cases), liver + lung (8 cases) and lymph nodes (3 cases). Twenty-four patients completed the entire treatment plan. The most common toxicities were transaminitis (16 patients, grade 3-4), diarrhea (six patients, grade 3), nausea/vomiting (one patient, grade 4), and asthenia (one patient, grade 3). The treatment was stopped in one patient because of prolonged grade 4 transaminitis. The adverse event profile was similar in the patients aged >65 years and <65 years. Complete responses were observed in 2 patients, partial responses in 12, stable disease in 23, and progression in 8.
Conclusions
The results of the study suggest that the raltitrexed plus oxaliplatin regimen is feasible and clinically active in advanced colorectal cancer.
De GramontA., BossetJ.F., MilanC., RougierP., BouchéO., EtienneP.L., MorvanF., LouvetC., GuillotT., FrançoisE., BedenneL.: Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluoruracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study.J Clin Oncol,15: 808–815, 1997.
2.
DouillardJ.Y., CunninghamD., RothA.D., NavarroM., JamesR.D., KarasekP., JandikP., IvesonT., CarmichaelJ., AlaklM., GruiaG., AwadL., RougierP.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial.Lancet,355: 1041–1047, 2000.
3.
SaltzL.B., CoxJ.V., BlankeC., RosenL.S., FehrenbacherL., MooreM.J., MarounJ.A., AcklandS.P., LockerP.K., PirottaN., ElfringG.L., MillerL.L.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.New Engl J Med,343: 905–914, 2000.
4.
De GramontA., FigerA., SeymourM., HomerinM., HmissiA., CassidyJ., BoniC., Cortes-FunesH., CervantesA., FreyerG., PapamichaelD., Le BailN., LouvetC., HendlerD., de BraudF., WilsonC., MorvanF., BonettiA.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol,18: 2938–2947, 2000.
5.
CassataA., StaniS.C., AlùM., ProcopioG., CortinovisD., BerettaE., FerrarioE., LongariniR., BaldiniA., LambiaseA., Di BartolomeoM., BuzzoniR., BidoliP., BajettaE.: Ongoing phase II trial with two schedules of irinotecan (CPT 11), in combination with capecitabine as first-line chemotherapy in patients with advanced colorectal cancer (ACRC).Proc ASCO,20: 144A, 2001.
6.
Van CutsemE., TwelvesC., CassidyJ., AllmanD., BajettaE., BoyerM., BugatR., FindlayM., FringsS., JahnM., McKendrickJ., OsterwalderB., Perez-MangaG., RossoR., RougierP., SchmiegelW.H., SeitzJ.F., ThompsonP., VieitezJ.M., WeitzelC., HarperP.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.J Clin Oncol,19: 4097–4106, 2001.
7.
RougierP., Van CutsemE., BajettaE., NiederleN., PossingerK., LabiancaR., NavarroM., MorantR., BleibergH., WilsJ., AwadL., HeraitP., JacquesC.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.Lancet352: 1407–1412, 1998.
8.
CocconiG., CunninghamD., Van CutsemE., FrancoisE., GustavssonB., van HazelG., KerrD., PossingerK., HietscholdS.M.: Open, randomized, multicentre trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.J Clin Oncol,16: 2943–2952, 1998.
9.
CunninghamD., ZalcbergJ.R., RathU., OliverI., van CutsemE., SvenssonC., SeitzJ.F., HarperP., KerrD., Perez-MangaG.: Final results of a randomized trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.Ann Oncol,7: 961–965, 1996.
10.
KöhneC.H., Thuss-PatienceP., FriedrichM., DanielP.T., KretzschmarA., BenterT., BauerB., DietzR., DörkenB.: Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.Br J Cancer,77: 973–977, 1998.
11.
BécouarnY., YchouM., DucreuxM., BoreiC., Bertheault-CvitkovicF., SeitzJ.F., NascaS., NguyenT.D., PaillotB., RaoulJ.L., DuffourJ., FandiA., Dupont-AndréG., RougierP.: Phase II trial of oxaliplatin as first line chemotherapy in metastatic colorectal cancer patients.J Clin Oncol,16: 2739–2744, 1998.
12.
FizaziK., DucreuxM., RuffiéP., BonnayM., DanielC., SoriaJ.C., HillC., FandiA., PoterreM., SmithM., ArmandJ.P.: Phase I, dose finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.J Clin Oncol,18: 2293–2300, 2000.
13.
ScheithauerW., KornekG.V., Ulrich-PurH., PenzM., RadererM., SalekT., HaiderK., KwasnyW., DepischD.: Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma. Results of a phase I-II trial.Cancer,91: 1264–1271, 2001.
14.
ScheithauerW., KomekG.V., SchuellB., Ulrich-PurH., PenzM., RadererM., LangF., SchneeweissB., LenauerA., DepischD.: Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.Ann Oncol,12: 709–714, 2001.
15.
SeitzJ-F, BennounaJ., PaillotB., GamelinE., FrançoisE., ConroyT., RaoulJ-L, BecouarnY., Bertheault-CvitkovicF., YchouM., NascaS., FandiA., BarthelemyP., DouillardJ.Y.: Multicentre non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal patients.Ann Oncol,13: 1072–1079, 2002.
16.
CascinuS., GrazianoF., FerraùF., CatalanoV., MassacesiC., SantiniD., SilvaR.R., BarniS., ZaniboniA., BattelliN., SienaS., GiordaniP., MariD., BaldelliA.M., AntognoliS., MaisanoR., PrioloD., PessiM.A., ToniniG., RotaS., LabiancaR.: Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).Ann Oncol,13: 716–720, 2002.
17.
NeriB., DoniL., FulignatiC., PerfettoF., TurriniM., AndreoliF., PantaloneD., PerniceL.M., TaruffiF., MartiniV., PomaA., ValeriA., BacciG., SancezL., MorettiR.: Raltitrexed plus oxaliplatin as first-line chemotherapy in metatstatic colorectal cancer: a multicentric phase II trial.Anticancer Drugs,13: 719–724, 2002.
18.
World Health Organization:Handbook for reporting results of cancer treatment.World Health Organization, Geneva1979.
19.
SimonR.: Optimal two stage designs for phase II clinical trials.Controlled Clin Trials,10: 1–10, 1989.
20.
MagnèN., FrancoisE., BroisinL., GuardiolaE., RamaioliA., FerreroJ.M., NamerM.: Palliative 5-fluoruracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10 years experience.Am J Clin Oncol,25: 126–130, 2002.
21.
Feliu J, Mel JR, Camps C, Escudero P, Aparicio J, Menéndez D, García Girón C, Rodriguez MR, Sánchez JJ, González Barón M, Oncopaz Cooperative Group Associated Hospitals:Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen.Eur J Cancer,38: 1204–1211, 2002.
22.
CunninghamD., ZalcbergJ., MarounJ., JamesR., ClarkeS., MaughanT.S., VincentM., SchulzJ., González BarónM., FacchiniT.: Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials.Eur J Cancer,38: 478–486, 2002.
23.
Tabah-FishI., Maindrault-GoebelF., BenavidesM., ZaniboniA., BigelowR., BleibergH.: Oxaliplatin/5FU/LV is feasible, safe and active in elderly colorectal cancer (CRC) patients.Proc ASCO,21: 140A, 2002.
